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Unique cytoplasmic loop regions of the G(,, %, 05 and as subunits of the GABAA receptor have been expressed in E. coli and used to generate polyclon- 
al antisera specific for these subunits. The antibodies identify proteins by SDS-polyacrylamide gel electrophoresis and western blotting of molecular 
size 51 kDa, 53 kDa, 59 kDa and 55 kDa, respectively, which show differential patterns of expression during development. Whereas the ol, and 
a, subunits are present at early stages, the expeession of aI and es subunits is low at birth and increases with age. This differential expression could 
be correlated with previous studies examining the developmental expression of 5Zl and BZ2 benzodiazepine binding sites. 
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1, INTRODUCTION 
The GABAA receptor is a multimeric ligand gated ion 
channel which possesses binding sites for the en- 
dogenous agonist GABA, as well as allosteric binding 
sites for benzodiazepines, barbiturates and steroids (for 
reviews ee [IJ]). The combination of subunits forming 
the GABAA receptor has yet to be clearly defined. 
Molecular cloning studies have so far revealed 6 types 
of a, 3 types of P, 2 types of y and one 6 subunit [2-41. 
It has been demonstrated that at least one (Y, one fi and 
one y subunit are required to reconstruct a GABAA 
receptor whose pharmacological and electrophysio- 
logical properties approach those of native receptors in 
vivo [J-7]. The cy subunit is of particular interest since 
it contains the primary binding site for benzodiazepines 
[g] and the type of m subunit present appears to define 
the pharmacology of receptors expressed in transfected 
cells [9- 111. 
In the present study we have demonstrated that there 
is differential expression of cy subunits at different 
stages of development in the rat brain and that it is 
possible to correlate this with the developmental expres- 
sion of [3H]benzodiazepine binding sites. 
2. MATERIALS AND METHODS 
Polyclonal antisera were raised against the unique cytoplasmic loop 
re8iOns Of the #I (v322-h12), a2 (V322-A382), 02 (PS47-T421) alld tys 
(Arks-Sass) subunits of the GAB& receptor as described elsewhere 
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[la]. Membranes were prepared from cortex, hippocampus, 
cerebellum and striatum of rat brain according to the method of Olsen 
et al. [13]. Tissue was taken from rats of the following ages: newborn 
(1 day), 7 days, 14 days, 3 months, I2 months and 18 months. Mem- 
branes were resuspended at a protein concentration of 2 m&ml, 
2Oc(g of membrane protein was loaded per lane for SDS- 
polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot- 
ting, and 5Org was used per tube for radioligand binding assays. 
Western blots were carried out using a 1:SOO dilution of antiserum 
[12] and radioligand assays were conducted with [3H]Ro 15-1788 
(2.5 nM), or [3H]flunitrazepam (2 nM) in 10 mM Tris-HCI, 1 mM 
EDTA, pH 7.5, for 1 h at 4T as previously described [12]. 
3. RESULT-S AND DISCUSSION 
In agreement with other studies using antipeptide an- 
tibodies [14-161 or polyclonal antisera raised against 
bacterially expressed GABAA protein [la], the an- 
tiserum detected LY subunit proteins of the appropriate 
sizes (LYI 50 kDa, CYZ 53 kDa, LYY~ 59 kDa, CYS 55 kDa) 
upon SDS-PAGE and Western blot analysis. The ai an- 
tiserum identified two bands in very young animals only 
(Fig. 1). The additional ower band may represent an 
immature form of the subunit with incomplete post- 
translational modification, e.g. incomplete glycosyla- 
tion. In tissue prepared from older rats this species is 
not observed. The cr3 antiserum identified a broad band 
at 59 kDa which could be resolved into a doublet in all 
regions studied. A lower molecular weight species of 
53 kDa was also inconsistently observed and this may 
well represent aproteolytic fragment, The most striking 
developmental pattern is observed with the ~YI and LYS 
subunits, Both are almost below detection level at birth 
and increase dramatically with maximum levels of ex- 
pression being reached by 3 months. This same pattern 
of expression for a~ was also observed in other brain 
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subunit this may represent different post-translational 
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Fig. 1. Developmental expression of at, CYZ. (~3 and cys subunits of the 
GABAp, receptor, Membranes were prepared from various brain 
regions of ISIS of the following ages. Newborn (NB), 7 day, 14 day, 
3 month, 12 month and 18 month, as indicated. 2Opg of membrane 
protein was applied per lane. subjected to SDS/lZ% PAGE and 
Western blotting, Blots were probed with a 1:500 dilution of 
antiserum and bands visualised with a peroxidase/cthylcarbazole 
reaction (123. Gels were calibrated with prestained molecular wt. 
markers (Amersham) and the positions of the 69 kDa and 46 kDa 
markers are indicated. Data shown are representative of 2 or 3 
experiments. 
regions such as the cortex (data not shown) and is con- 
sistent with immunochemical localisation of CYI subunits 
on cerebellar granule cells only after several days of 
maturation [ 171 and the steady increase in CYI mRNA in 
whole rat brain up to 25 days after birth [ 18,231. The 
low level of expression of the CYS subunit in brain areas 
other than the hippocampus precluded the detection of 
a consistent pattern of developmental expression. 
The pattern of developmental expression for CYZ and 
cys subunits was quite different from that seen with LYI 
and cyg subunits. Both subunits were present at high 
levels at birth and both showed a tendency to decline in 
aged rats (greater than 12 months old), This is in accord 
with photoaffinity labelling experiments which reveal 
two bands labelled with [‘H]flunitrazepam in young 
animals of 53 kDa and 59 kDa presumably the CYZ and 
GYP subunits, respectively [l&19,22], and a much heavier 
labelling of a 51 kDa protein (the LYI subunit) in mature 
rats [19]. In newborn animals the band detected by the 
IYJ antiserum appeared to be a doublet, and like the LYI 
modifications. 
Early studies investigating the development of bind- 
ing sites for [‘H]benzodiazepines howed there to be no 
change in the kDa for any of the ligands with age 
[20,21]. We therefore used one concentration of ligand 
to measure the number of benzodiazepine binding sites 
in the same membranes that were used for Western blot 
analysis. As shown in Fig. 2, the number of 
13H]flunitrazepam and [3H]Ro 15-1788 binding sites in- 
creased from newborn to adult levels at 14 days, after 
which time they remained fairly constant. A similar pat- 
tern has previously been observed using the ligand 
[3H]diazepam [20]. It is currently held that the ligando 
[3H]flunitrazepam, [3H]Ro 15-1788 and [3H]diazepam 
bind with high affinity to the same sites, i.e. receptors 
composed of either CYI, CYYZ, ~3 or ~(5 together with ,& and 
yz ]I 2]. Therefore the increase in expression of recep- 
tors containing at and as must more than compensate 
for the decrease in receptors containing a2 and cy3 
subunits to result in a net increase in benzodiazepine 
binding. The al subunit has been shown in transfected 
cells to correlate well with GABAA receptors exhibiting 
a BZl pharmacology [lo] whereas BZ2 type receptors 
may contain a~, cy3 or cyg subunits 19,111. The increase 
in the developmental expression of the (~1 subunit 
parallels earlier studies demonstrating an increase in the 
expression of BZI receptors with age as measured by 
GL218,872 displacement of [3H]flunitrazepam binding 
[21]. Similarly, the abundance of cyz and cy3 subunits 
early on in development is consistent with the observa- 
tion that BZ2 receptor binding sites are already present 
5-rT-mm d 18 
Days M&l: 
Fig, 2. Binding of [‘H]fhmitratepam (2 nM; S--O), and 
tJH)Ro 15-1788 (2.5 nM, w) to cortical (a) and cercbcllar (b) 
mctnbrancs prcpmd from rats of various ages, Data show are 
mcilti s SE or 4 cxperinrents~ 
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at high levels in newborn rats [21]. GABAA receptors 
containing w or cyg subunits have not been considered 
because mRNA for the a2 subunit is very rare in rat 
brain [24] and expressed receptors containing the a6 
subunit are reported not to bind classical ben- 
zodiazepines with high affinity [9]. 
191 Euddens, H., Pritchett, D.B., Kohler, M., Killisch. I., 
Keinanen, K., Monyer, J-f., Sprengel. R. and Seeberg, PH. 
(1990) Nature 346, 648-651. 
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245, 1389-1392. 
We have clearly shown here differential expression of 
GABAn receptor cv subunits during development. 
Whether other subunits (8, y and 6) are also differen- 
tially expressed during development remains to be 
determined. Characterization of the developmental ex- 
pression of GABAA receptor subtypes may yield some 
clues towards understanding their role in nerve 
transmission, 
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